市場調查報告書

Evobrutinib(M2951):新的考察與到2030年為止的預測

Evobrutinib (M2951) - Emerging Drug Insight and Market Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 968219
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Evobrutinib(M2951):新的考察與到2030年為止的預測 Evobrutinib (M2951) - Emerging Drug Insight and Market Forecast - 2030
出版日期: 2020年10月31日內容資訊: 英文 50 Pages
簡介

Evobrutinib(M2951),是Breton型蛋白酪氨酸激酶(BTK)高選擇性的抑制劑,不直接影響T細胞,設計用來阻斷主要的B細胞反應,例如抗體和細胞因子的增殖和釋放。BTK抑制認將為抑制自身抗體產生細胞,並且臨床前研究表明,可能在某些自身免疫性疾病的治療是有用的。

本報告提供美國,德國,法國,義大利,西班牙,英國,日本主要7個國家的類風濕性關節炎臨床實驗藥Evobrutinib(M2951)調查,提供醫藥品概要,市場評估,SWOT分析,分析師的見解,競爭產品,其他新的治療藥等資訊。

目錄

第1章 醫藥品概要

  • 產品詳細內容
  • 作用機制
  • 投藥和管理
  • 研究開發活動
    • 臨床開發
    • 安全性和有效性
  • 其他開發活動

第2章 市場評估

  • 主要7個國家的市場分析
  • 美國市場
  • 德國市場
  • 法國市場
  • 義大利市場
  • 西班牙市場
  • 英國市場
  • 日本市場

第3章 SWOT分析

第4章 分析師的見解

第5章 競爭產品

第6章 其他新的治療方法

第7章 附錄

第8章 報告的購買選擇

目錄
Product Code: DIDM0074

"Evobrutinib (M2951) - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Rheumatoid Arthritis in 7 Major Markets. A detailed picture of the EVOBRUTINIB (M2951) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Overview:

Evobrutinib (M2951) is in clinical development to investigate its potential as a treatment for multiple sclerosis (MS). It is an oral, highly selective inhibitor of Bruton's Tyrosine Kinase (BTK) which is important in the development and functioning of various immune cells including B lymphocytes and macrophages. Evobrutinib is designed to inhibit primary B cell responses such as proliferation and antibody and cytokine release, without directly affecting T cells. BTK inhibition is thought to suppress autoantibody-producing cells, which preclinical research suggests may be therapeutically useful in certain autoimmune diseases.

Scope of the report:

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug research and development activity details across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around Evobrutinib (M2951).
  • The report contains forecasted sales for Evobrutinib (M2951) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase II) for Rheumatoid Arthritis.
  • The report also features the SWOT analysis with analyst insights and key findings of Evobrutinib (M2951).

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Evobrutinib (M2951) Analytical Perspective by DelveInsight

  • In-depth Evobrutinib (M2951) Market Assessment

This report provides a detailed market assessment of Evobrutinib (M2951) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.

  • Evobrutinib (M2951) Clinical Assessment

The report provides the clinical trials information of Evobrutinib (M2951) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights:

  • In the coming years, the market scenario for Rheumatoid Arthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Evobrutinib (M2951) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other emerging products for Rheumatoid Arthritis are giving market competition to Evobrutinib (M2951) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current development scenario of Evobrutinib (M2951).
  • Our in-depth analysis of the forecasted sales data of Evobrutinib (M2951) from 2020 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Evobrutinib (M2951).

Key Questions:

  • Which company is developing Evobrutinib (M2951) along with the phase of the clinical study?
  • What is the technology utilized in the development of Evobrutinib (M2951)?
  • What is the product type, route of administration and mechanism of action of Evobrutinib (M2951)?
  • What is the clinical trial status of the study and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Evobrutinib (M2951) development?
  • What are the key designations that have been granted to Evobrutinib (M2951)?
  • What is the forecasted market scenario of Evobrutinib (M2951)?
  • What is the history of Evobrutinib (M2951) and what is its future?
  • What is the forecasted sales of Evobrutinib (M2951) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how these are giving competition to Evobrutinib (M2951)?
  • Which are the late-stage emerging therapies under development for the treatment of the PPD?

Table of Contents

1. Drug Overview

  • 1.1. Product Detail
  • 1.2. Mechanism of Action
  • 1.3. Dosage and Administration
  • 1.4. Research and development activity
    • 1.4.1. Clinical Development
    • 1.4.2. Safety and Efficacy
  • 1.5. Other Development Activities

2. Market Assesment

  • 2.1. 7MM Market Analysis
  • 2.2. The United States Market
  • 2.3. Germany Market
  • 2.4. France Market
  • 2.5. Italy Market
  • 2.6. Spain Market
  • 2.7. United Kingdom Market
  • 2.8. Japan Market

3. SWOT Analysis

4. Analyst Views

5. Market Competitors

6. Other Emerging Therapies

7. Appendix

8. Report Purchase Options

List of Tables

  • Table 1 EVOBRUTINIB (M2951), Description
  • Table 2 EVOBRUTINIB (M2951), Clinical Trial Description
  • Table 3 EVOBRUTINIB (M2951), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Table 4 Market Competitors
  • Table 5 Other Emerging Therapies

List of Figures

  • Figure 1 The Development Timeline of EVOBRUTINIB (M2951)
  • Figure 2 Patent Details, EVOBRUTINIB (M2951)
  • Figure 3 EVOBRUTINIB (M2951), 7MM Market Size from 2020 to 2030 (in Million USD)
  • Figure 4 EVOBRUTINIB (M2951), US Market Size from 2020 to 2030 (in Millions USD)
  • Figure 5 EVOBRUTINIB (M2951), EU5 Market Size from 2020 to 2030 (in Millions USD)
  • Figure 6 EVOBRUTINIB (M2951), Japan Market Size from 2020 to 2030 (in Millions USD)